Sarah Meibusch

Sarah Meibusch is Partner and Head of Healthcare at OneVentures, where she leads the firm’s healthcare pillar and focuses on sourcing and supporting life sciences companies developing transformative technologies with global potential. OneVentures says she currently serves as Chair of Vaxxas and Axial Therapeutics, a Board Member for Kira Biotech, and an Alternate Board Member and Observer for Clinical Genomics and Prota Therapeutics.

She joined OneVentures in 2017 as an Investment Manager when the firm was building the team for its A$170 million Healthcare Fund III, a fund focused on Australian companies commercialising drugs, medical devices and diagnostics in or near clinical development. She was later promoted to Partner in 2022 and appointed Head of Healthcare in 2026.

Before OneVentures, Meibusch worked across life sciences business development and commercial strategy in Australia and the United States. OneVentures said she had spent five years scouting technologies for Shire Pharmaceuticals across Australia, New Zealand, Singapore, Taiwan, Korea and Japan, including sourcing the Fibrotech transaction. She also held senior roles at Progen Pharmaceuticals, the University of Queensland’s QAAFI institute, Beef CRC and Pyxis Genomics.

Her education includes a Bachelor of Agricultural Science with First Class Honours from the University of Queensland and a master’s degree in genomics from Cornell University. She has post-graduate training in negotiation from Harvard and is a Graduate of the Australian Institute of Company Directors. She is also listed as a member of the QIMR Berghofer Medical Research Institute Commercial Advisory Board and the AusBiotech Investment Advisory Group.

• OneVentures’ healthcare thesis, as stated on its healthcare page, is to back “transformative technology that will deliver best-in-class patient outcomes with global reach and impact.”
• Meibusch said in a Bionics Institute interview that OneVentures backs outstanding teams, sound business models, strong forecasts, global potential and opportunities to disrupt a market.
• For life sciences, she said the technology must be “truly game changing,” either first-in-class or best-in-class, and must address an unmet medical need while fitting the fund mandate and return horizon.
• OneVentures’ healthcare mandate screens for companies that are privately owned and unlisted, clinical stage or less than a year from first-in-human studies, and developing first- or best-in-class products for large unmet medical need.
• Meibusch said OneVentures typically does not invest “super early stage”; for equity investments it needs to deploy enough capital, usually A$10 million to A$25 million, with a first check “maybe a Series A, but more likely a Series B.”
• OneVentures emphasizes milestone-based investing: proof of clinical efficacy and safety, quality science, and a clear regulatory and reimbursement path.
• The firm describes itself as hands-on, supporting portfolio companies with commercialisation strategy, industry connections, governance, capital strategy and global expansion.